Slpi decreases proliferation and arrest cell cycle in jurkat acute t-lymphocytic leukemia cells.

REITERI RM, GUERRIERI D, AMIANO N, MAFIA P, TATEOSIAN N, CHULUYAN E.

Cordoba, Argentina

Congreso; 7º congreso de la Asociacion Latinoamericana de Inmunologia; 2005

ALAI

AbstractIn our ongoing research into anti-inflammatory compounds, we have described a serine proteinase inhibitor, SLPI for activity related to T-cell functionality. SLPI inhibited T cell receptor-mediated proliferation in human peripheral blood T cells in a concentration-dependent manner. In the present study, we have investigated the dose-dependent effects of SLPI on growth of Jurkat. Different concentration of SLPI was added and proliferation was measured through the aggregate of 3H-thymidine. Significant (n=5, p< 0,05) suppression of cell proliferation became evident after 24 h of treatment, and was most pronounced at the highest concentration (8mg/ml) of SLPI (Figure). Following, in order to unravel the mechanism how SLPI decreases T cell proliferation, we examined the effect of SLPI on cell cycle progression. Jurkat cells were treated with SLPI and samples were taken every 90 minutes. Then propidium iodide was added to the samples.  The reduction of cell proliferation, was accompanied by measurable changes in distribution of cells at different phases of the cell cycle, as assayed by flow cytometry. We observed that SLPI arrest the cells at G1. These results suggest that SLPI inhibits proliferation in leukemia cell by the action over cell cycle, arresting the cell in G1 state. Thus, our findings suggest that SLPI merits further study as an agent against leukemia.